Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer’s Xalkori Joins The Six-Figure Oncology Drug Club

Executive Summary

The roll-out of Pfizer Inc.’s new personalized non-small cell lung cancer therapy Xalkori blends right in with the prevailing trends in cancer drug launches, proving that six-figure pricing now seems to be the new black in oncology.
Advertisement

Related Content

Oncology PROs: Limited Use Due To Small Trials, Fast Drug Development
Genentech’s Alecensa Joins The ALK Inhibitor Market
Looking Beyond Drugs For High Cancer Costs
Seattle Genetics Will Test Oncology Pricing Acceptance With Adcetris
Pfizer’s Crizotinib Eases Past FDA With Targeted Population
What New Cancer Pathway Programs Mean For The Drug Industry
What New Cancer Pathway Programs Mean For The Drug Industry
Express Scripts Reports Specialty Drug Spending Steadily Rising, And Pipelines Show More To Come
Provenge Poised For Broad Insurance Coverage, Despite Grumbles On Price
Provenge Poised For Broad Insurance Coverage, Despite Grumbles On Price

Topics

Advertisement
UsernamePublicRestriction

Register

PS053745

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel